The INPP5F Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the INPP5F gene. INPP5F encodes a phosphoinositide 5-phosphatase that hydrolyzes PtdIns(4,5)P2 and PtdIns(3,4,5)P3, key messengers in signal transduction. This polyclonal loss-of-function model enables robust interrogation of INPP5F’s role in phosphoinositide metabolism, actin dynamics, and endocytosis without clonal bias, suitable for functional genomics and drug discovery studies.
The parental A-549 cell line is established from a 58-year-old male with lung adenocarcinoma and carries an activating KRAS G12S mutation, a common oncogenic driver. These epithelial cells serve as a widely used model for respiratory epithelium biology, non-small cell lung cancer, and therapeutic resistance. The KRAS mutation renders them particularly valuable for studying cross-talk between RAS-MAPK and PI3K/AKT pathways, as KRAS can activate PI3K. INPP5F’s function as a negative regulator of PI3K/AKT signaling makes this genetic background highly pertinent for exploring how INPP5F loss synergizes with oncogenic KRAS to modulate cancer cell behavior.
INPP5F functions as a phosphatidylinositol 5-phosphatase that preferentially dephosphorylates the D-5 position of PtdIns(4,5)P2 and PtdIns(3,4,5)P3, thereby attenuating PI3K/AKT signaling, actin remodeling, and clathrin-mediated endocytosis. It is activated downstream of receptor tyrosine kinases and PI3K, and interacts with endocytic regulators such as RAB5, OCRL, and APPL1. INPP5F modulates actin polymerization through CDC42 and RAC1, and its activity reduces AKT phosphorylation and clathrin-coated pit assembly. By depleting PtdIns(4,5)P2, INPP5F impacts vesicle scission and cell migration, positioning it as a critical node linking lipid signaling to cytoskeletal dynamics and trafficking.
In A-549 cells, INPP5F knockout is anticipated to elevate PtdIns(3,4,5)P3 levels and augment PI3K/AKT signaling, potentially enhancing proliferation, survival, and migration downstream of mutant KRAS. Disrupted phosphoinositide balance may alter clathrin-mediated endocytosis, affecting receptor internalization and signal termination. Given INPP5F’s links to glioblastoma and breast cancer invasion, this knockout model provides insight into lung adenocarcinoma progression, drug resistance, and metastasis. The interplay of INPP5F loss with KRAS G12S enables dissection of phosphoinositide metabolism’s contribution to epithelial-mesenchymal transition and oncogenic signaling.
Research applications include western blotting of phospho-AKT (Ser473) to assess PI3K pathway activation, immunofluorescence for F-actin and clathrin dynamics, Transwell migration assays, and endocytosis assays. These polyclonal knockout cells support high-throughput screening of PI3K/AKT or endocytosis modulators and viability assays for chemosensitivity studies. For additional information, please contact Ascent Research.
